Creative Planning
BIO icon

Creative Planning’s Bio-Rad Laboratories Class A BIO Stock Holding History

Creative Planning’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.78M Buy
9,974
+6,525
+189% +$1.88M ﹤0.01% 1645
2025
Q4 		$1.05M Buy
3,449
+21
+0.6% +$6.55K ﹤0.01% 2244
2025
Q3 		$961K Buy
3,428
+631
+23% +$172K ﹤0.01% 2152
2025
Q2 		$675K Buy
2,797
+518
+23% +$122K ﹤0.01% 2198
2025
Q1 		$555K Buy
2,279
+98
+4% +$29.5K ﹤0.01% 2192
2024
Q4 		$716K Buy
2,181
+549
+34% +$186K ﹤0.01% 1909
2024
Q3 		$546K Buy
1,632
+93
+6% +$29.5K ﹤0.01% 2028
2024
Q2 		$420K Sell
1,539
-426
-22% -$124K ﹤0.01% 2082
2024
Q1 		$680K Buy
1,965
+58
+3% +$19.1K ﹤0.01% 1631
2023
Q4 		$616K Buy
1,907
+369
+24% +$116K ﹤0.01% 1555
2023
Q3 		$551K Buy
1,538
+127
+9% +$49K ﹤0.01% 1501
2023
Q2 		$535K Sell
1,411
-70
-5% -$28.5K ﹤0.01% 1503
2023
Q1 		$709K Buy
1,481
+123
+9% +$57.6K ﹤0.01% 1272
2022
Q4 		$571K Sell
1,358
-66
-5% -$26.6K ﹤0.01% 1358
2022
Q3 		$594K Buy
1,424
+247
+21% +$123K ﹤0.01% 1224
2022
Q2 		$583K Buy
1,177
+96
+9% +$50K ﹤0.01% 1235
2022
Q1 		$609K Buy
1,081
+1
+0.1% +$603 ﹤0.01% 1228
2021
Q4 		$816K Hold
1,080
– – ﹤0.01% 1047
2021
Q3 		$806K Buy
1,080
+22
+2% +$16.5K ﹤0.01% 1050
2021
Q2 		$682K Sell
1,058
-21
-2% -$12.8K ﹤0.01% 1106
2021
Q1 		$616K Buy
1,079
+475
+79% +$281K ﹤0.01% 1291
2020
Q4 		$352K Buy
604
+58
+11% +$33K ﹤0.01% 1520
2020
Q3 		$281K Buy
546
+9
+2% +$4.56K ﹤0.01% 1454
2020
Q2 		$242K Buy
+537
New +$237K ﹤0.01% 1426
2020
Q1 		– Sell
-1,161
Closed -$430K – 1886
2019
Q4 		$430K Buy
1,161
+429
+59% +$151K ﹤0.01% 1196
2019
Q3 		$244K Buy
732
+21
+3% +$6.85K ﹤0.01% 1487
2019
Q2 		$222K Sell
711
-12
-2% -$3.59K ﹤0.01% 1547
2019
Q1 		$221K Sell
723
-218
-23% -$58.8K ﹤0.01% 1513
2018
Q4 		$219K Sell
941
-445
-32% -$119K ﹤0.01% 1429
2018
Q3 		$434K Sell
1,386
-94
-6% -$29.2K ﹤0.01% 1169
2018
Q2 		$427K Buy
1,480
+7
+0.5% +$1.93K ﹤0.01% 1156
2018
Q1 		$368K Sell
1,473
-86
-6% -$21.9K ﹤0.01% 1240
2017
Q4 		$372K Buy
1,559
+1
+0.1% +$242 ﹤0.01% 1244
2017
Q3 		$346K Buy
1,558
+177
+13% +$39.8K ﹤0.01% 1245
2017
Q2 		$313K Buy
1,381
+301
+28% +$65.6K ﹤0.01% 1271
2017
Q1 		$215K Buy
1,080
+33
+3% +$6.36K ﹤0.01% 1440
2016
Q4 		$191K Buy
1,047
+40
+4% +$6.82K ﹤0.01% 1434
2016
Q3 		$165K Buy
1,007
+124
+14% +$18.8K ﹤0.01% 1512
2016
Q2 		$126K Hold
883
– – ﹤0.01% 1524
2016
Q1 		$121K Sell
883
-4
-0.5% -$525 ﹤0.01% 1512
2015
Q4 		$123K Buy
887
+24
+3% +$3.33K ﹤0.01% 1505
2015
Q3 		$116K Buy
+863
New +$124K ﹤0.01% 1510
2015
Q2 		– Sell
-840
Closed -$114K – 1299
2015
Q1 		$114K Buy
840
+590
+236% +$73.1K ﹤0.01% 1505
2014
Q4 		$30K Hold
250
– – ﹤0.01% 2338
2014
Q3 		$28K Buy
250
+214
+594% +$25.4K ﹤0.01% 2292
2014
Q2 		$4K Buy
+36
New +$4.4K ﹤0.01% 3291

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Creative Planning's BIO Position: Q1 2026 in Review

Creative Planning increased its Bio-Rad Laboratories Class A (BIO) stake by 189% in Q1 2026, buying an estimated $1.88M and bringing the position to 9,974 shares worth $2.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1645.

Creative Planning first reported a position in BIO in Q2 2014 and has held it in 46 quarters since. 391 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Creative Planning held 9,974 shares of Bio-Rad Laboratories Class A worth $2.78M as of Q1 2026.
  • Creative Planning bought 6,525 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $1.88M.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #1645 holding.
  • Creative Planning first reported a position in Bio-Rad Laboratories Class A in Q2 2014 and has held it in 46 quarters since.
  • 391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.